Affiliations 

  • 1 Department of Epidemiology and Biostatistics, Research Institute for Tropical Medicine, Manila, Philippines
  • 2 Medical Department, Research Institute for Tropical Medicine, Manila, Philippines
  • 3 BJ Medical College and Sassoon General Hospital, Pune, India
  • 4 Department of Pediatrics, Sanglah Hospital, Udayana University, Bali, Indonesia
  • 5 Infectious Diseases Department, Children's Hospital 1, Ho Chi Minh City, Vietnam
  • 6 Infectious Diseases Department, Children's Hospital 2, Ho Chi Minh City, Vietnam
  • 7 National Center for HIV/AIDS, Dermatology and STD, Phnom Penh, Cambodia
  • 8 Infectious Diseases Department, National Hospital of Pediatrics, Hanoi, Vietnam
  • 9 Department of Pediatrics, Faculty of Medicine and Research Unit in Pediatric and Infectious Diseases, Chulalongkorn University, Bangkok, Thailand
  • 10 Department of Pediatrics, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
  • 11 Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo, Jakarta, Indonesia
  • 12 Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 13 Pediatric Institute, Women and Children Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 14 Department of Pediatrics, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand
  • 15 Department of Pediatrics, Hospital Likas, Kota Kinabalu, Malaysia
  • 16 VHS-Infectious Diseases Medical Centre, Chennai, India
  • 17 Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
  • 18 Department of Pediatrics, Penang Hospital, Penang, Malaysia
  • 19 Department of Pediatrics, Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia
  • 20 TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok, Thailand
  • 21 The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia
PLoS One, 2023;18(9):e0291523.
PMID: 37708128 DOI: 10.1371/journal.pone.0291523

Abstract

Despite improvements in HIV testing and earlier antiretroviral therapy (ART) initiation in children living with HIV through the years, a considerable proportion start treatment with advanced disease. We studied characteristics of children and adolescents living with HIV and their level of immunodeficiency at ART initiation using data from a multi-country Asian cohort. We included children and adolescents who were ART-naïve and <18 years of age at ART initiation from 2011 to 2020 at 17 HIV clinics in six countries. Incidence rates of opportunistic infections (OIs) in the first two years of triple-drug ART (≥3 antiretrovirals) was also reported. Competing risk regression analysis was performed to identify factors associated with first occurrence of OI. In 2,027 children and adolescents (54% males), median age at ART initiation increased from 4.5 years in 2011-2013 to 6.7 in 2017-2020, median CD4 count doubled from 237 cells/μl to 466 cells/μl, and proportion of children who initiated ART as severely immunodeficient decreased from 70% to 45%. During follow-up, 275 (14%) children who received triple-drug ART as first treatment and had at least one clinic visit, developed at least one OI in the first two years of treatment (9.40 per 100 person-years). The incidence rate of any first OI declined from 12.52 to 7.58 per 100 person-years during 2011-2013 and 2017-2020. Lower hazard of OIs were found in those with age at first ART 2-14 years, current CD4 ≥200 cells/μl, and receiving ART between 2017 and 2020. The analysis demonstrated increasing number of children and adolescents starting ART with high CD4 count at ART start. The rate of first OI markedly decreased in children who started ART in more recent years. There remains a clear need for improvement in HIV control strategies in children, by promoting earlier diagnosis and timely treatment.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.